AIM ImmunoTech IncNYSE American:AIM
- LAST PRICE0.4282
- TODAY'S CHANGE (%)0.0217 (5.3383%)
- Bid / Lots0.4282/ 1
- Ask / Lots0.4300/ 13
- Open / Previous Close0.4100 / 0.4065
- Day Range
- 52 Week Range
- Volume85,255
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AIM |
|---|---|---|
| 09:32 ET | 5399 | 0.41 |
| 09:38 ET | 250 | 0.41 |
| 09:39 ET | 100 | 0.425 |
| 09:45 ET | 403 | 0.41 |
| 09:52 ET | 1214 | 0.4101 |
| 09:57 ET | 1579 | 0.4101 |
| 11:00 ET | 1750 | 0.4249 |
| 11:02 ET | 991 | 0.4101 |
| 11:09 ET | 499 | 0.4111 |
| 11:24 ET | 110 | 0.411 |
| 11:49 ET | 200 | 0.4249 |
| 12:07 ET | 235 | 0.425 |
| 12:21 ET | 10752 | 0.424999 |
| 12:23 ET | 9925 | 0.425 |
| 12:25 ET | 10000 | 0.425 |
| 12:27 ET | 10000 | 0.425 |
| 12:30 ET | 10000 | 0.425 |
| 12:57 ET | 730 | 0.4175 |
| 01:24 ET | 1000 | 0.417499 |
| 01:42 ET | 2930 | 0.4173 |
| 02:00 ET | 1000 | 0.4174 |
| 02:08 ET | 100 | 0.4174 |
| 02:09 ET | 500 | 0.4171 |
| 02:27 ET | 385 | 0.4165 |
| 02:36 ET | 5192 | 0.4168 |
| 02:47 ET | 270 | 0.413401 |
| 02:49 ET | 1200 | 0.4101 |
| 03:14 ET | 2480 | 0.4289 |
| 03:16 ET | 265 | 0.4195 |
| 03:36 ET | 480 | 0.410101 |
| 03:41 ET | 100 | 0.4276 |
| 03:59 ET | 609 | 0.4282 |
Apr 25, 2024
AIM ImmunoTech Announces Release of the Next CEO Corner Segment, from 8:45AM ET on Thursday Apr 25, 2024 by Dow Jones
8:45AM ET on Thursday Apr 25, 2024 by Dow JonesPress Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment, from 8:45AM ET on Thursday Apr 25, 2024 by Dow Jones
8:45AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 18, 2024
AIM ImmunoTech Announces Release of the Next CEO Corner Segment, from 8:45AM ET on Thursday Apr 18, 2024 by Dow Jones
8:45AM ET on Thursday Apr 18, 2024 by Dow JonesPress Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment, from 8:45AM ET on Thursday Apr 18, 2024 by Dow Jones
8:45AM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 15, 2024
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs, from 8:55AM ET on Monday Apr 15, 2024 by Dow Jones
8:55AM ET on Monday Apr 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
AIM ImmunoTech Inc | 20.3M | -0.7x | --- |
RenovoRx Inc | 20.4M | -1.2x | --- |
CERo Therapeutics Holdings Inc | 20.8M | -3.6x | --- |
Evaxion Biotech A/S | 21.5M | -0.1x | --- |
Vincerx Pharma Inc | 19.2M | -0.4x | --- |
Biora Therapeutics Inc | 21.8M | -0.1x | --- |
Company Information
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Contact Information
- Headquarters
- 2117 SW Highway 484OCALA, FL, United States 34473-7949
- Phone
- 352-448-7797
- Fax
- 352-480-4620
Executives
- Independent Chairman of the Board
- William Mitchell
- President, Chief Executive Officer, Executive Vice Chairman
- Thomas Equels
- Chief Financial Officer
- Robert Dickey
- Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Secretary
- Peter Rodino
- Chief Scientific and Medical Officer
- David Strayer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $20.3M |
|---|---|
Revenue (TTM) | $202.0K |
Shares Outstanding | 49.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.11 |
EPS | $-0.59 |
Book Value | $0.21 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 100.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -15,800.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
